Myovant Sciences Ltd. (NYSE:MYOV) Files An 8-K Material Modification to Rights of Security Holders
Item 3.03 Material Modifications to Rights of Security Holders.

(d) Exhibits

Myovant Sciences Ltd. Exhibit
EX-3.1 2 d513530dex31.htm EX-3.1 EX-3.1 Exhibit 3.1 THIRD AMENDED AND RESTATED BYE-LAWS OF MYOVANT SCIENCES LTD. TABLE OF CONTENTS   Interpretation 1.   Definitions   1 Shares 2.   Power to Issue Shares   5 3.   Power of the Company to Purchase its Shares   6 4.   Rights Attaching to Shares   6 5.   Calls on Shares   9 6.   Forfeiture of Shares   10 7.   Share Certificates   11 8.   Fractional Shares   12     Registration of Shares 9.   Register of Members   12 10.   Registered Holder Absolute Owner   13 11.   Transfer of Registered Shares   13 12.   Transmission of Registered Shares   14 Alteration of Share Capital 13.   Power to Alter Capital   16 14.   Variation of Rights Attaching to Shares   16 Dividends and Capitalisation 15.   Dividends   17 16.   Power to Set Aside Profits   18 17.   Method of Payment   18 18.   Capitalisation   19 Meetings of Members 19.   Annual General Meetings   19 20.   Special General Meetings   19 21.   Requisitioned General Meetings   20 22.   Notice   20 23.   Giving Notice and Access   21 24.   Notice of Nominations and Member Business   22 25.   Postponement or Cancellation of General Meeting   27 26.   Electronic Participation and Security at General Meetings   28 27.   Quorum at General Meetings   28 28.   Chairman to Preside at General Meetings   29 29.   Voting on Resolutions   29 30.   Power to Demand Vote on Poll   30 31.   Voting by Joint Holders of Shares   31 32.   Votes of Members – General   31 33.   Adjustment of Voting Power   32 34.   Other Adjustments of Voting Power   33 35.   Notice   33 36.   Board Determination Binding   34 37.   Requirement to Provide Information and Notice   34 38.   Instrument of Proxy   35 39.   Representation of Corporate Member   36 40.   Adjournment of General Meeting   37 41.   Written Resolutions   37 42.   Directors Attendance at General Meetings   39 Directors and Officers 43.   Election of Directors   39 44.   Classes of Directors   39 45.   Term of Office of Directors   39 46.   Alternate Directors   39 47.   Removal of Directors for Cause   41 48.   Vacancy in the Office of Director   41 49.   Remuneration of Directors   42 50.   Defect in Appointment   42 51.   Directors to Manage Business   42 52.   Powers of the Board of Directors   43 53.   Register of Directors and Officers   44 54.   Appointment of Officers   44 55.   Appointment of Secretary   44 56.   Duties of Officers   45 57.   Remuneration of Officers   45 58.   Conflicts of Interest   45 59.   Indemnification and Exculpation of Directors and Officers   46     Meetings of the Board of Directors 60.   Board Meetings   47 61.   Notice of Board Meetings   48 62.   Electronic Participation in Meetings   48 63.   Quorum at Board Meetings   48 64.   Board to Continue in Event of Vacancy   48 65.   Chairman to Preside   49 66.   Written Resolutions   49 67.   Validity of Prior Acts of the Board   49 Corporate Records 68.   Minutes   49 69.   Place Where Corporate Records Kept   50 70.   Form and Use of Seal   50 Accounts 71.   Books of Account   50 72.   Financial Year End   51 Audits 73.   Annual Audit   51 74.   Appointment of Auditor   51 75.   Remuneration of Auditor   51 76.   Duties of Auditor   51 77.   Access to Records   52 78.   Financial Statements   52 79.   Distribution of Auditor’s Report   52 80.   Vacancy in the Office of Auditor   52 Business Combinations 81.   Business Combinations   52 Voluntary Winding-Up and Dissolution 82.   Winding-Up   60 Changes to Constitution 83.   Changes to Bye-laws   60 84.   Changes to the Memorandum of Association   60 85.   Discontinuance   60 86.   Amalgamation or Merger   61     Myovant Sciences Ltd.    Page 1                   INTERPRETATION   1. Definitions     1.1 In these Bye-laws,…
To view the full exhibit click here

About Myovant Sciences Ltd. (NYSE:MYOV)

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.